Cargando…
Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours
Identifying a strategy with strong efficacy against non-inflamed tumours is vital in cancer immune therapy. ERY974 is a humanized IgG4 bispecific T cell-redirecting antibody that recognizes glypican-3 and CD3. Here we examine the combination effect of ERY974 and chemotherapy (paclitaxel, cisplatin,...
Autores principales: | Sano, Yuji, Azuma, Yumiko, Tsunenari, Toshiaki, Kayukawa, Yoko, Shinozuka, Junko, Fujii, Etsuko, Amano, Jun, Nishito, Yukari, Maruyama, Toru, Kinoshita, Yasuko, Sakamoto, Yuichiro, Yoshida, Ayae, Miyazaki, Yoko, Sato, Yuta, Teramoto-Seida, Chifumi, Ishiguro, Takahiro, Tanaka, Takayoshi, Kitazawa, Takehisa, Endo, Mika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452528/ https://www.ncbi.nlm.nih.gov/pubmed/36071036 http://dx.doi.org/10.1038/s41467-022-32952-3 |
Ejemplares similares
-
Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial
por: Komatsu, Shun-ichiro, et al.
Publicado: (2022) -
Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate
por: Waaijer, Stijn JH, et al.
Publicado: (2020) -
Enhancing the antitumor potency of T cells redirected by bispecific antibodies
por: Chang, Chien-Hsing, et al.
Publicado: (2017) -
Influence of the bispecific antibody IgG subclass on T cell redirection
por: Kapelski, Stephanie, et al.
Publicado: (2019) -
T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2020)